These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23190395)

  • 1. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.
    Gushwa NN; Kang S; Chen J; Taunton J
    J Am Chem Soc; 2012 Dec; 134(50):20214-7. PubMed ID: 23190395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
    Hill ZB; Perera BG; Maly DJ
    Mol Biosyst; 2011 Feb; 7(2):447-56. PubMed ID: 21060940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural study of ponatinib in inhibiting SRC kinase.
    Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
    Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy.
    Hah JM; Sharma V; Li H; Lawrence DS
    J Am Chem Soc; 2006 May; 128(18):5996-7. PubMed ID: 16669643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
    Kwarcinski FE; Fox CC; Steffey ME; Soellner MB
    ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
    Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
    J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A biosensor of SRC family kinase conformation by exposable tetracysteine useful for cell-based screening.
    Irtegun S; Wood R; Lackovic K; Schweiggert J; Ramdzan YM; Huang DC; Mulhern TD; Hatters DM
    ACS Chem Biol; 2014 Jul; 9(7):1426-31. PubMed ID: 24828008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
    Johnson TK; Soellner MB
    Bioconjug Chem; 2016 Jul; 27(7):1745-9. PubMed ID: 27266260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
    Fang L; Vilas-Boas J; Chakraborty S; Potter ZE; Register AC; Seeliger MA; Maly DJ
    ACS Chem Biol; 2020 Jul; 15(7):2005-2016. PubMed ID: 32479050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
    Register AC; Chakraborty S; Maly DJ
    Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for selective inhibition of Src family kinases by PP1.
    Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
    Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
    Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
    J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective NMR probe to monitor the conformational transition from inactive to active kinase.
    Xie Q; Fulton DB; Andreotti AH
    ACS Chem Biol; 2015 Jan; 10(1):262-8. PubMed ID: 25248068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on dual Src/Abl inhibitors.
    Musumeci F; Schenone S; Brullo C; Botta M
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active site profiling reveals coupling between domains in SRC-family kinases.
    Krishnamurty R; Brigham JL; Leonard SE; Ranjitkar P; Larson ET; Dale EJ; Merritt EA; Maly DJ
    Nat Chem Biol; 2013 Jan; 9(1):43-50. PubMed ID: 23143416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
    Schenone S; Manetti F; Botta M
    Mini Rev Med Chem; 2007 Feb; 7(2):191-201. PubMed ID: 17305593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.